Introduction
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is a rare chronic autoimmune cholestatic liver disease characterized by lymphocytic cholangitis, gradual destruction of the small intrahepatic bile ducts, leading to fibrosis, and potential cirrhosis through resulting complications. It is found to be highly prevalent in women, with a female to male diagnostic ratio of about 10 to 1 [1, 2] . Currently, the first-line and standard therapy established for PBC care is ursodeoxycholic acid (UDCA), but nearly 40% patients have incomplete biochemical response to UDCA, and this has been associated with the increased risk of progression to end-stage liver disease, and the worse transplant-free survival rates, compared with UDCA-responsive patients [3] [4] [5] . Several potential mechanisms have been proposed for immune-mediated bile duct damage injury in PBC, including the roles of T cells, B cells, NK cells and other cell phenotypes. The immunological interaction between biliary epithelial cells and surrounding inflammatory cells is an important mechanism underlying biliary damage injury [6] [7] [8] [9] . In particular, dysfunctional immune responses are crucial for the pathogenesis of PBC. However, the precise process of autoimmune responses in the pathogenesis of PBC remains unknown.
Previous studies have reported that the follicular helper T (Tfh) cells are the helper T cell subset that localizes in germinal centres within secondary lymphoid organs. They support B cells to produce high-affinity antibodies and generate B cell memory. Thus, excessive Tfh cells contribute to the development of autoimmunity and lymphoid malignancy [10] . Recently, follicular regulatory T (Tfr) cells were defined as a specialized population of Tregs which are primarily located in germinal centres and suppress the GC reaction after immunization and thus play an opposing role with Tfh cells in the regulation of humoral immunity. Both Tfh cells and Tfr cells highly express CXCR5 (C-X-C motif chemokine receptor 5), PD-1 (programmed death 1), ICOS (inducible T cell costimulator) and Bcl6 (B cell lymphoma 6). In addition, Tfr cells are thought to originate from thymic-derived Treg precursors and have unique characteristics distinguished from Tfh cells by the expressions of FoxP3, CD25, CTLA-4 (CTL-associated antigen 4) and GITR (glucocorticoid-induced TNFR-related protein) [11, 12] . Accumulating evidence has demonstrated that abnormal either Tfr cells or Tfh cells activity may result in the dysregulation of immune tolerance and abnormal production of high levels of autoantibodies and thereby contribute to the pathogenesis of autoimmune responses [11, 12] . However, the roles that Tfr cells and Tfh cells play in PBC remain unclear. In this study, we detected the percentages of circulating Tfh cells and Tfr cells based on the additional markers CD25 and CD127 [13, 14] .
The [15] . Previous reports also suggested that an aberrant distribution of circulating memory Tfh cell subsets contributes to the pathogenesis of some autoimmune diseases. High levels of Tfh2 were found in the patients with Sjogren's syndrome, and higher levels of Tfh2 and Tfh17 were expressed in juvenile dermatomyositis [15, 16] [17] .
In this study, the subsets frequencies and the phenotypic characterizations of circulating Tfh cells and Tfr cells were assessed to examine their roles in the immunopathogenesis of PBC. We found a significantly lower Tfr/Tfh ratio in the peripheral blood of PBC patients in comparison with healthy controls. Our results suggest that the imbalance of circulating Tfr/Tfh ratio involves in the pathogenesis of PBC and offer a new biomarker for estimating immunological states and potential targets for the development of novel therapies for patients with PBC.
Materials and methods
Subjects. The recruited participants were divided into two groups, including 34 PBC patients and 27 health individuals. The diagnosis of PBC was based on established criteria [3] . Assays of serum liver function, autoimmune antibodies and immunoglobulin and liver ultrasound were performed for all participants. HBsAg and anti-HCV were also tested to exclude HBV and HCV infection. The enrolled participants were outpatients and inpatients from the department of Gastroenterology of Peking University Third Hospital during 2015-2016. This study was approved by the ethics committee of Peking University, and informed consents were obtained from all participants.
Flow cytometry analysis. Intracellular cytokines staining. For the CTLA-4 expression, intracellular cytokines staining was performed by Fixation/Permeabilization kit (BD Biosciences) according to the manufacture's protocol. Briefly, after the surface antigen staining, cells were washed twice with staining buffer and were pelleted by centrifugation; thoroughly resuspended cells were added fixation/permeabilization solution for 20 min at 4°C. After that, cells were washed twice with washing buffer and were pelleted by 
Results

Characteristics of study subjects
Overall, the recruited subjects with overall characteristics were described in Table 1 . The majority (31/34) of PBC cases were women, and all patients with PBC were antimitochondrial antibody (AMA) positive. Approximately 74% (25/34) were on UDCA therapy as the sole Fig. 1A . Comparing with healthy controls, Tfh cells expression increased (P = 0.0326), but Tfr cells and Tfr/Tfh ratio (P = 0.0024) declined in PBC patients (Fig. 1B) . Further, we detected the proportions of Tfh cells, Tfr cells and Tfr/Tfh ratio in different PBC subgroups.
Tfr cells and Tfr/Tfh ratio were downregulated among patients with PBC who did not receive UDCA therapy compared with those who received UDCA therapy ( Fig. 2A) . Similarly, decreased Tfr cells and Tfr/Tfh ratio were also observed in patients with PBC who did not respond to UDCA therapy compared with those who responded to UDCA therapy (Fig. 2B) , and PBC patients with liver cirrhosis compared with asymptomatic PBC patients (Fig. 2C) . Although there were no significant differences, the above results suggest that the decreased Tfr cells coupled with increased Tfh cells are involved in immunopathogenesis of PBC. ............................................................................................................................................................ ... compared with healthy controls (Fig. 3B) (Fig. 4A, B) . These results suggested ICOS and CTLA-4 are implicated in regulating humoral immunity thus participate in pathogenesis of PBC. [17] . Here, we detected the different expression profiles of Tfh cells and Tfr cells defined by CCR7 and PD-1 (Fig. 5A) . We found the percentages of effector memory Tfh cells (P = 0.0017) and effector memory Tfr cells (P = 0.0500) are greater in patients with PBC than those in healthy controls. Oppositely, the percentages of central memory Tfh cells (P = 0.0012) and central memory Tfr cells significantly decreased in PBC patients compared with healthy individuals (Fig. 5B) . The phenotypic analysis implied the dominance of the effector phenotype in PBC patients which correlated with autoimmune disease activities.
Distributions of Th1/Th2/Th17 subtypes defined by CXCR3 and CCR6 in Tfh cells and Tfr cells
It has been reported that circulating CD4 + CXCR5 + T cells also comprise three subsets: T helper 1(Th1), Th2 and Th17 cells according to the expression of CXCR3 and CCR6 [15] (Fig. 6A) . Results showed that Tfh2 cells (P = 0.0302) and Tfr2 cells (P = 0.0015) were significantly downregulated among PBC patients compared with healthy individuals (Fig. 6B, C ). There were no statistical differences in Tfh1 cells and Tfr1cells, Tfh17 cells and Tfr17 cells expressions between PBC patients compared with healthy controls (Fig. 6B, C) . Previous study has confirmed that Tfh2 and Tfh17 cells efficiently induce naive B cells to differentiate into plasmablasts, whereas Tfh1 cells are incapable of doing so [15] . So we evaluated the ratios of (Tfh2 + Tfh17)/Tfh1 and (Tfr2 + Tfr17)/Tfr1, the ratio of (Tfh2 + Tfh17)/ Tfh1 was slightly increased but the ratio of (Tfr2 + Tfr17)/Tfr1 was slightly decreased in PBC patients compared with healthy controls (Fig. 6B, C) ,these results may imply the enhanced humoral immune response in pathogenesis of PBC in certain extent.
Correlations between different cell subsets and clinical indicators
Correlation between Tfh/Tfr cell subsets and clinical indicators was summarized in Fig. 7 . The Tfr/Tfh ratio 
Discussion
Accumulating evidence suggests that Tfh cells are critically involved in the pathogenesis of autoimmune diseases, including PBC [6, 7] . In addition, a specialized subset of Treg cells, Tfr cells was also found to play a suppressive role in GC reactions. Given that Tfh and Tfr cells are reciprocal and antagonistic regulators of GC responses, a balance of their actions is critical for immune homoeostasis. An aberrant or disordered Tfr/Tfh ratio results in the disruption of this balance and the development of autoimmune diseases [21] . Our study presents reliable evidence of the imbalances between circulating Tfh cells and Tfr cells in patients with PBC. In consistent with previous studies [6] , we confirmed a higher amount of cTfh cells in patients with PBC. Furthermore, we presented the first description of the reduced cTfr cells and cTfr/Tfh ratio in patients with PBC, and the reduced Tfr/Tfh ratio showed inverse correlation with serum level of IgM. It is known that elevated level of IgM and the presence of AMA are characteristic of the sera of patients with PBC. The increase in serum IgM has been attributed to chronic B cell Decreased Tfr/Tfh Ratio in Primary Biliary Cholangitis 457 activation via the TLR-signalling pathway [22] . Interestingly, although there were no statistical differences, decreased value of Tfr/Tfh ratio was also found in newly diagnosed PBC patients without UDCA drug compared with patients with that therapy. Previous reports have revealed that up to 40% of patients with PBC failed to respond adequately to UDCA and did not improve their liver biochemistry [3, 4] . These patients with incomplete biochemical response to UDCA are referred to as 'UDCA non-responders' and in comparison with UDCA responders, they have poorer prognosis due to greater risk of diseases progression, higher mortality risk and likelihood to require liver transplantation [1] . In our study, among the patients under UDCA treatment, Tfr/Tfh ratio was slightly reduced in UDCA non-responders compared with UDCA responders. Meanwhile, this trend was also existed in PBC patients already suffering from liver cirrhosis compared with patients with no obvious symptoms. Taken together, our data further suggest that decreased Tfr cells and increased Tfh cells result in the disruption of the immune homoeostasis, vigorous GC reaction, excessive antibody production and accelerated immunopathological process in PBC.
Otherwise, we observed a diminished CTLA-4 expression in Tfr cells in PBC patients in comparison with healthy controls. Same trends were also observed in these subgroups: (1) PBC without UDCA therapy versus patients with UDCA therapy, (2) UDCA non-responders versus responders and (3) PBC with cirrhosis versus asymptomatic PBC. The role of CTLA-4 in autoimmune disease has been elucidated in recent studies. CTLA-4 is essential for immunological tolerance [23, 24] . It has been reported that Tfr cells constitutively express higher amount of CTLA-4 in comparison with total Treg population [12] . lo PD-1 hi subset correlated with elevated autoantibody profiles and more severe disease activities. In addition, the previous studies reported that different subsets with Th1, Th2 or Th17 features possess discrete capabilities to support B cells producing antibodies [26] [27] [28] [29] . It was proved that Th2 and Th17 subsets can efficiently induce naive B cells to produce immunoglobulins and to switch isotypes through IL-21 secretion [26] [27] [28] [29] . While Th2 subtype can promote IgG and IgE secretion, Th17 cells are efficient in promoting IgG and, in particular, IgA secretion. In contrast, Th1 subset does not produce IL-21 and lack the capacity to help naive B cells [26] [27] [28] [29] . We detected no obvious increased percentages of Th2 and Th17 subtypes when compared PBC to Health controls although there were slightly increased Tfh17 cells and Tfr cells in PBC. This result suggests Tfh17cells and Tfr17cells may partially take part in the pathogenesis of PBC more or less; larger cohort may still be needed to verify this effect in the future.
There are still some limitations in the present study. The first is the relatively small sample size, especially for the sample numbers in different subgroups which may lead to the no statistical differences when comparing the cell subsets distributions in different subgroups. These data may be confirmed in larger scale studies and in other populations from different regions. Secondly, we did not perform the subsets frequencies and the phenotypic characterizations of Tfh cells and Tfr cells in the lymphoid tissues and liver tissues of patients with PBC although recent reports have indicated that circulating Tfh cells derived from GC-Tfh cells and shuffling between peripheral blood and lymphoid tissue [15] . Thirdly, functional studies of how Tfh cells and Tfr cells modulate GC reactions and B cells response are still required to uncover the precise molecular mechanisms during the pathogenic process of PBC.
Taken together, our study described the subset distribution and phenotypes of circulating Tfh cells and Tfr cells and their relationships with clinical indicators. Our study indicates that unbalanced circulating Tfr/Tfh ratio and aberrant distribution of effector/resting phenotypes of Tfh cells or Tfr cells may contribute to the immunopathogenesis of PBC. The Tfr/Tfh ratio may serve as a useful biomarker for patients with PBC, leading to new strategies for tailoring treatment of PBC.
